Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop

Circulation

Volumn 96, Issue 7, 1997, Pages 2272-2279

  Ueno, Hikaru ^a   Haruno, Akihiro ^a   Morisaki, Nobuhiro ^a   Furuya, Mayumi ^a   Kangawa, Kenji ^a   Takeshita, Akira ^a   Saito, Yasushi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Genes; Natriuretic peptides; Restenosis; Viruses

Indexed keywords

NATRIURETIC PEPTIDE TYPE C; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; GENE TRANSFER; GROWTH REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; RAT; SMOOTH MUSCLE FIBER;

EID: 0030881753     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.7.2272     Document Type: Article

References (44)

1. Ross R. The pathogencsis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981-993.
3. Schwartz SM, deBlois D, O'Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465. /
4. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle" cell proliferation after arterial injury. Science. 1994;265:781-784.
5. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
6. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirusmediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
7. Ueno H, Masuda S, Li J-J, Nishio S, Yamamoto H, Takeshita A. Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann NYAcad Sei. 1997;811:401-411.
8. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90: 944-951.
9. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-nyb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
10. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Nail Acad Sei USA. 1993;90:8474-8478.
11. Indolfi C, Awedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, Chiariello M. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1: 541-545.
12. Ueno H, Yamamoto H, Ito S, Li J-J, Takeshita A. Adenovirusmediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Tliromb Vase Biol. 1997;17:898-904.
13. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide: a new member of natriuretic peptide family identified in porcine brain. Biochem Biopliys Res Commun. 1990;168: 863-870.
14. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel DV. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991;252:120-123.
15. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, Matsuo H. C-tjpe natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177:927-931.
16. Porter JG, Catalanor R, McEnroe G, Lewicki JA, Protter AA. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Physiol. 1992;263:C1001C1006.
17. Ikeda M, Kohno M, Takeda T. Inhibition by cardiac natriuretic peptides of rat vascular endothelial cell migration. Hypertension. 1995;26:401-405.
18. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet. 1992;340:622.
19. Furuya M, Aisaka K, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, Minamino N, Kangawa K, Matuso H. C-type natriuretic peptide inhibits intimai thickening after vascular injury. Biochem Biophys Res Commun. 1993;193:248-253.
20. Ueno H, Li J-J, Tomita H, Yamamoto H, Pan Y, Kanegae Y, Saito I, Takeshita A. Quantitative analysis of repeated adenovirusmediated gene transfer into injured canine femoral arteries. Arteriosder Tliromb Vase Biol. 1995;15:2246-2253.
21. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Nail Acad Sei USA. 1996;93:1320-1324.
22. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirusmediated transfer of a truncated transforming growth factor(TGF)-/3 type II receptor completely and specifically abolishes diverse signaling by TGF-/3 in vascular wall cells in primary culture. / Biol Client. 1996;271:16253-16259.
23. Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of a cDNA encoding a precursor for rat C-type natriuretic peptide (CNP). FEES Lett. 1990;276:209-213.
24. Tawaragi Y, Fuchimura K, Tanaka S, Minamino N, Kangawa K, Matsuo H. Gene and precursor structure of human C-type natriuretic peptide. Biochem Biophys Res Commun. 1991;175:645-651.
25. Niwa H, Yamamura K, Miyazaki J. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene. 1991; 108:193-200.
26. Li J-J, Ueno H, Pan Y, Tomita H, Yamamoto H, Kanegae Y, Saito I, Takeshita A. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res. 1995:30:97-105.
27. Minamino N, Kangawa K, Matuso H. N-terminally extended form of C-type natriuretic peptide (CNP-53) identified in porcine brain. Biochem Biophys Res Commun. 1990;170:973-979.
28. Furuya M, Tawaragi Y, Minamitake Y, Kitajima Y, Fuchimura K, Tanaka S, Minamino K, Kangawa K, Matsuo H. Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 1992;183:964-969.
29. Ohyama Y, Miyamoto K, Morishita Y, Matsuda Y, Saito Y, Minamino N, Kangawa K, Matsuo H. Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist. Biochem Biophys Res Commun. 1992;189:336-342.
30. Shinomiya M, Tashiro J, Saito Y, Yoshida S, Furuya M, Oka N, Tanaka S, Kangawa K, Matsuo H. C-type natriuretic peptide inhibits intimai thickening of rabbit carotid artery after balloon catheter injury. Biochem Biophys Res Commun. 1994;205: 1051-1056.
31. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviralmediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293-298.
32. Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr Rev. 1994;15:135-162.
33. Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VWM. cGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cejls. Circ Res. 1995;76:199-208.
34. Foils J. An in vivo model of Experimental arterial stenosis, intimai damage, and periodic thrombosis. Circulation. 1991;83(suppl IV): IV-3-IV-14.
35. Matsumura T, Kugiyama K, Sugiyama S, Ohgushi M, Yamanaka K, Suzuki M, Yasue H. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophil-induced endothelial cytotoxicity. J Clin Invest. 1996;97: 2192-2203.
36. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43: 109-142.
37. Marumo T, Nakaki T, Hishikawa K, Hirahashi J, Suzuki H, Kalo R, Saruta T. Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3',5'-monophosphate elevation in vascular smooth muscle cells. Endocrinology. 1995;136: 2135-2142.
38. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cordial. 1991;17:758-769.
39. Wight TN. The extracellular matrix and atherosclerosis. Curr Opin Lipidol. 1995;6:326-334.
40. Maack T, Suzuki M, Amleida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor.'Sc;e;;ce. 1987;238:675-678.
41. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptidcs, urodilatin, C-type natriuretic peptide and some C-receptor liuands by endopeptidase-24,11. Biochem J. 1993; 291:83-88.
42. Komatsu Y, Itoh H, Suga S, Igaki T, Ogawa Y, Kishimoto I, Nakagawa O, Yoshimasa T, Nakao K. Regulation of secretion and clearance of C-type natriuretic peptide in the interaction of vascular endothelial cells and smooth muscle cells. J Hyperteiis. 1996;14: 585-592.
43. Itoh H, Nakao K. Antagonism between vascular renin-angiotensin system and vascular natriuretic peptide system. Blood Pressure. 1994;3:49-53.
44. Suga S, Nakao K, Kishimoto I, Hosoda K, Mukoyama M, Arai H, Shirakami G, Ogawa Y, Komatsu Y, Nakagawa O, Hama N, ImurarH. Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells. Circ Res. 1992;71:34-39.